SHENGDA BIO-PHARM released its first-quarter performance, with a net profit attributable to the parent company of 21.7095 million yuan, a year-on-year increase of 469.35%
I'm PortAI, I can summarize articles.
SHENGDA BIO-PHARM released its Q1 2025 performance report, with operating revenue of 203 million yuan, a year-on-year increase of 9.95%. The net profit attributable to the parent company was 21.7095 million yuan, a year-on-year increase of 469.35%; the net profit after deducting non-recurring gains and losses was 19.7178 million yuan, a year-on-year increase of 1749.87%. The basic earnings per share were 0.13 yuan/share
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments